PeptiDream Announces Collaboration, License Agreement with Lilly

PeptiDream (PeptiDream)(TOKYO:4587), announced that they have entered into a Collaboration and License Agreement with US-based Eli Lilly and Company (Lilly)

on 19 December 2013. Under the agreement, PeptiDream will identify macrocyclic peptides as potential drug candidates for disease targets being pursued by Lilly. PeptiDream will leverage its proprietary Peptide Discovery Platform System (PDPS) technology for translational synthesis, selection, and screening of nonstandard macrocyclic peptides, and Lilly will be responsible for any subsequent research and development as pharmaceutical candidates. Under the terms of the Agreement, PeptiDream will receive an undisclosed upfront payment, research funding and milestone payments upon the successful achievement of certain development milestones.